HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Raloxifene Hydrochloride

HCID 54900
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
82640-04-8
Standard SMILES
Cl.O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12
InChIKey
BKXVVCILCIUCLG-UHFFFAOYSA-N
Molecular formula
C28H28ClNO4S
Average molar mass
510 g/mol
Monoisotopic mass
509.14275706

Overview

Raloxifene hydrochloride is a hydrochloride salt resulting from the reaction of equimolar amounts of raloxifene and hydrogen chloride. It has a role as a bone density conservation agent, an estrogen receptor modulator and an estrogen antagonist. It contains a raloxifene(1+).

Names & identifiers

Preferred name
Raloxifene Hydrochloride
IUPAC
[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone;hydrochloride
English name
Raloxifene hydrochloride
Molecular formula
C28H28ClNO4S
Molecular weight
510.04

Names & synonyms

RALOXIFENE HYDROCHLORIDE82640-04-8Raloxifene HclEvistaKeoxifene hydrochlorideOptrumaRaloxifene TevaDTXSID1034181LY156758LY 156758NSC-706725LY-156758
Show more names
(6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)Methanone hydrochlorideCS-127KEOXIFENELY 139481AKOS 92138RALOXFENE HCLLY156758 hydrochlorideLY139481 hydrochloride
4F86W47BR6DTXCID9014181CHEBI:50740NSC706725[6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochlorideLY139481OstiralRazylan

Database identifiers

CAS
82640-04-8
PubChem CID
54900
DTXSID
DTXSID1034181
ChEMBL

Properties

Computed structural properties

Topological polar surface area
98.2 Ų
Hydrogen bond donors
3
Hydrogen bond acceptors
6
Rotatable bonds
7
Heavy atoms
35
Formal charge
0
Complexity
655

Experimental & physicochemical properties

Human Drugs · 5 items

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Collision Cross Section213.4 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physicochemical properties

Melting point
250 · 250-253°C
storage temp.
2 · 2-8°C
solubility
28 mg/mL, · DMSO: 28 mg/mL, soluble
form
solid
color
light yellow
λmax
286 nm · 286nm(lit.)
Merck
14 · 14,8098
BCS Class
2 · 2
Major Application
pharmaceutical (small molecule)
InChI
1S/C28H27NO4S.ClH/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29;/h4-13,18,30-31H,1-3,14-17H2;1H

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H351 (82.4%): Suspected of causing cancer [Warning Carcinogenicity]

P203, P273, P280, P318, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 68 reports by companies from 16 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesCarc. 2 (82.4%)

Toxicology

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Raloxifene hydrochloride

vLess-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Safety data

wgk
3
rtecs
PC4956925
hs_code
2934990002
risk_code
36/37/38
Signal word
Warning
Symbol(GHS)
GHS08
hazard_code
Xi
safety_code
22-24/25
Storage Class
11 - Combustible Solids
Hazard statements
H351-H361d

Chemistry & industry

Pharmacology

FDA Pharmacological Classification · 2 items

RALOXIFENE HYDROCHLORIDE

Estrogen Agonist/Antagonist [EPC]; Selective Estrogen Receptor Modulators [MoA]

MeSH Pharmacological Classification · 3 items

Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds.

A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63)

Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.

Applications · 5 items

DescriptionRaloxifene was launched as Evista in the US for the prevention of postmenopausal osteoporosis. It is noteworthy that this molecule was formerly under development as keoxifene for breast cancer and prostatic hypertrophy. Raloxifene can be prepared by acylation of 6-methoxy-2-(4-methoxyphenyl) benzothiophene followed by simultaneous demethylation of both methoxy groups. Raloxifen is a selective estrogen receptor modulator, exerting antiestrogenic action on certain tissues (breast) and also estrogenic action on bone metabolism or serum lipids. In normal early postmenopausal women, 200 mg daily produced a trend towards suppression of estrogen effects. Raloxifen impeded bone loss in osteoporosis. A two-year study in postmenopausal women with an increased risk for osteoporosis showed that Raloxifen markedly prevented non-traumatic vertebral fractures. Results of several clinical studies demonstrated that Raloxifen appreciably reduced the risk of developing breast cancer. Moreover, it had favourable effect on lipid profiles without having the potential side-effects of estrogen-based therapies. Several extensions for different uses of this molecule are planned, for example growth disorder, obesity, colon tumor and skin atrophy. No serious drug-related events have been reported in the limited number of clinical trials.

Related reactions

26 records
New reaction record
HRID 1490 reaction equation
HRID 1490As reactant
HRID 325154 reaction equation
HRID 325154As reactant
HRID 325162 reaction equation
HRID 325162As reactant
HRID 374950 reaction equation
HRID 374950As reactant
HRID 374951 reaction equation
HRID 374951As reactant
HRID 400096 reaction equation
HRID 400096As reactant
HRID 481286 reaction equation
HRID 481286As reactant
HRID 482552 reaction equation
HRID 482552As reactant
PreviousPage 1 of 4

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
CHEMBL1116
ChEBI
CHEBI:50740
UNII
4F86W47BR6
EC Number
639-789-7
InChIKey
BKXVVCILCIUCLG-UHFFFAOYSA-N
SMILES
C1(C(=O)C2C=CC(OCCN3CCCCC3)=CC=2)C2C=CC(O)=CC=2SC=1C1C=CC(O)=CC=1.Cl
CAS DataBase Reference
82640 · 82640-04-8(CAS DataBase Reference)
NCI Dictionary of Cancer Terms
raloxifene hydrochloride
FDA UNII
4 F86W47BR6 · 4F86W47BR6
NCI Drug Dictionary
raloxifene hydrochloride
UNSPSC Code
41116107 · 41116107
NACRES
24 · NA.24
Protein binding
98 · 98-99%
Excreted unchanged in urine
0.2 % · <0.2%
Volume of distribution
2348 · 2348(L/kg)
Biological half-life
27.7 · 27.7 / Unchanged
Symbol(GHS)
8 · GHS08
Signal word
Warning
Hazard statements
351 · H351-H361d
Precautionary statements
201 · P201-P202-P280-P308+P313-P405-P501
Hazard Codes
Xi
Risk Statements
36 · 36/37/38
Safety Statements
22 · 22-24/25
WGK Germany
3 · 3
RTECS
4956925 · PC4956925
HS Code
2934990002 · 2934990002
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
2 Repr · Carc. 2Repr. 2
Hazard Classifications
Carc. 2Repr. 2
Precautionary statements
P201-P202-P280-P308+P313-P405-P501

UsesRaloxifene hydrochloride can be used as a nonsteroidal, selective estrogen receptor modulator (SERM). Antiosteoporotic.

Usesamino acid, nutrient. A nonsteroidal, selective estrogen receptor modulator (SERM). Antiosteoporotic.Insoluble in water.

UsesLabeled Raloxifene, intended for use as an internal standard for the quantification of Raloxifene by GC- or LC-mass spectrometry.

General DescriptionPharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards

Upstream & downstream products

Upstream raw materials

(4-(2-(Piperidin-1-yl)ethoxy)phenyl)(6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl)methanone6-Methoxy-2-(4-methoxy phenyl)-benzo[b]thien-3-yl][4-[2-(1-[piperidinyl)ethoxy]phenyl]methanone hydrochloride

Downstream products

Raloxifene

Additional notes

DefinitionChEBI: A hydrochloride salt resulting from the reaction of equimolar amounts of raloxifene and hydrogen chloride.